Gilead Sciences, Inc.

SEC CIK: 0000882095

SEC filings (opens in a new tab)

In the past year, 1 open-market purchase filing worth – and no sales.

Current role at each company

ASMB Assembly Biosciences, Inc.10% Owneras of May 27, 2026
XLO Xilio Therapeutics, Inc.10% Owneras of Feb 17, 2026
RCUS Arcus Biosciences, Inc.10% Owneras of Feb 20, 2025
KYTX Kyverna Therapeutics, Inc.10% Owneras of Feb 13, 2024
KLRS Kalaris Therapeutics, Inc.10% Owneras of Jun 28, 2023

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought: –; 1 filing
Sold: –; 0 filings
Net: –; Bought minus sold
Companies: 1; With open-market trades

Trades

Every Form 4 that lists Gilead Sciences, Inc. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

Transaction type

Role

Minimum value (USD)

Filed from

Filed to

Filing delay at least (days)

Filing delay at most (days)

XLO Xilio Therapeutics, Inc.

10% Owner6 trades

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Feb 17, 2026 (view filing)	Feb 13	4 days	Gilead Sciences, Inc.10% Owner	PPurchase	+3.74M	$0.53	+$1.98M	–40.4M after	Derivative
Jun 6, 2025 (view filing)	Jun 5	1 day	Gilead Sciences, Inc.10% Owner	PPurchase	+53.3M	–	–	–13.3M after	Derivative4 lots
Dec 19, 2024 (view filing)	Dec 18	1 day	Gilead Sciences, Inc.10% Owner	PPurchase	+1.76M	$1.04	+$1.83M	+24.0%9.11M after
Dec 19, 2024 (view filing)	Dec 18	1 day	Gilead Sciences, Inc.10% Owner	PPurchase	+6.09M	$1.04	+$6.34M	–9.98M after	Derivative
Apr 3, 2024 (view filing)	Apr 2	1 day	Gilead Sciences, Inc.10% Owner	PPurchase	+485.3K	$0.76	+$368.8K	+7.1%7.35M after
Apr 3, 2024 (view filing)	Apr 2	1 day	Gilead Sciences, Inc.10% Owner	PPurchase	+3.88M	$0.76	+$2.95M	–3.88M after	Derivative

ASMB Assembly Biosciences, Inc.

10% Owner5 trades

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Oct 3, 2025 (view filing)	Aug 8	56 daysLate	Gilead Sciences, Inc.10% Owner	PPurchase	+2.30M	–	–	+103.9%4.51M after
Oct 3, 2025 (view filing)	Aug 8	56 daysLate	Gilead Sciences, Inc.10% Owner	PPurchase	+2.30M	–	–	–1.15M after	Derivative2 lots
Dec 23, 2024 (view filing)	Dec 19	4 days	Gilead Sciences, Inc.10% Owner	PPurchase	+940.5K	$21.37	+$20.1M	+74.1%2.21M after
Jun 20, 2024 (view filing)	Jun 17	3 days	Gilead Sciences, Inc.10% Owner	PPurchase	+179.5K	–	–	+16.5%1.27M after
Jun 20, 2024 (view filing)	Jun 17	3 days	Gilead Sciences, Inc.10% Owner	PPurchase	+179.5K	–	–	–179.5K after	Derivative

RCUS Arcus Biosciences, Inc.

10% Owner3 trades

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change
Feb 20, 2025 (view filing)	Feb 18	2 days	Gilead Sciences, Inc.10% Owner	PPurchase	+1.36M	$11.00	+$15.0M	+4.5%31.4M after
Jan 31, 2024 (view filing)	Jan 29	2 days	Gilead Sciences, Inc.10% Owner	PPurchase	+15.2M	$21.00	+$320.0M	+102.8%30.1M after
Jun 30, 2023 (view filing)	Jun 28	2 days	Gilead Sciences, Inc.10% Owner	PPurchase	+1.01M	$19.26	+$19.5M	+7.3%14.8M after

KYTX Kyverna Therapeutics, Inc.

10% Owner1 trade

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Feb 13, 2024 (view filing)	Feb 12	1 day	Gilead Sciences, Inc.10% Owner	PPurchase	+910.0K	$22.00	+$20.0M	+28.3%4.13M after

KLRS Kalaris Therapeutics, Inc.